Immunotherapy with STING and TLR9 agonists promotes synergistic therapeutic efficacy with suppressed cancer-associated fibroblasts in colon carcinoma

Overview of attention for article published in Frontiers in immunology, October 2023

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (57th percentile)
Good Attention Score compared to outputs of the same age and source (72nd percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 3 Dimensions

Readers on

mendeley: 7 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 33,201 followers.

RT @FrontImmunol: New Research: Immunotherapy with STING and TLR9 agonists promotes synergistic therapeutic efficacy with suppressed cancer…

16 Oct 2023

Reply Repost Favourite

RT @FrontImmunol: New Research: Immunotherapy with STING and TLR9 agonists promotes synergistic therapeutic efficacy with suppressed cancer…

15 Oct 2023

Reply Repost Favourite

RT @FrontImmunol: New Research: Immunotherapy with STING and TLR9 agonists promotes synergistic therapeutic efficacy with suppressed cancer…

14 Oct 2023

Reply Repost Favourite

New Research: Immunotherapy with STING and TLR9 agonists promotes synergistic therapeutic efficacy with suppressed cancer-associated fibroblasts in colon carcinoma: The innate immune sensing of nucleic acids using effective immunoadjuvants is… https://t.co

14 Oct 2023

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.